Literature DB >> 19593320

Polycystic ovary syndrome: a major unrecognized cardiovascular risk factor in women.

Carolyn J Alexander1, Edward P Tangchitnob, Norman E Lepor.   

Abstract

The prevalence of polycystic ovary syndrome (PCOS) is estimated to be nearly 10% among reproductive age women. PCOS may represent the largest underappreciated segment of the female population at risk of cardiovascular disease. Clinicians providing care to women of childbearing age must recognize the presenting clues, including irregular menses, hirsutism, alopecia, hyperandrogenemia, and obesity. The pathophysiology of PCOS is complex, involving the hypothalamus-pituitary-ovarian axis, ovarian theca cell hyperplasia, hyperinsulinemia, and a multitude of other cytokine- and adipocyte-driven factors. Cardiac risk factors associated with PCOS have public health implications and should drive early screening and intervention measures. There are no consensus guidelines regarding screening for cardiovascular disease in patients with PCOS. Fasting lipid profiles and glucose examinations should be performed regularly. Carotid intimal medial thickness examinations should begin at age 30 years, and coronary calcium screening should begin at age 45 years. Treatment of the associated cardiovascular risk factors, including insulin resistance, hypertension, and dyslipidemia, should be incorporated into the routine PCOS patient wellness care program.

Entities:  

Mesh:

Year:  2009        PMID: 19593320

Source DB:  PubMed          Journal:  Rev Cardiovasc Med        ISSN: 1530-6550            Impact factor:   2.930


  9 in total

1.  Preliminary data on effects of metformin on PED/PEA-15 cellular levels in obese women with polycystic ovary syndrome.

Authors:  S Savastano; R Valentino; G Pizza; A De Rosa; F Orio; F Passaretti; P Formisano; G Lombardi; F Beguinot; A Colao
Journal:  J Endocrinol Invest       Date:  2010 Jul-Aug       Impact factor: 4.256

2.  A 16-year-old girl with bilateral optic disc swelling.

Authors:  Usman Mahmood; Syed M Asad Ali; Mohammad Samir Dowlut; Mohammad Samir Dowlut; Bala Manoj
Journal:  Digit J Ophthalmol       Date:  2011-03-12

3.  Effect of metformin and flutamide on insulin, lipogenic and androgen-estrogen signaling, and cardiometabolic risk in a PCOS-prone metabolic syndrome rodent model.

Authors:  M Kupreeva; A Diane; R Lehner; R Watts; M Ghosh; S Proctor; D Vine
Journal:  Am J Physiol Endocrinol Metab       Date:  2018-08-28       Impact factor: 4.310

4.  Different Effects of Myoinositol plus Folic Acid versus Combined Oral Treatment on Androgen Levels in PCOS Women.

Authors:  Ali Cenk Ozay; Ozlen Emekci Ozay; Recep Emre Okyay; Erkan Cagliyan; Tuncay Kume; Bulent Gulekli
Journal:  Int J Endocrinol       Date:  2016-11-02       Impact factor: 3.257

5.  In depth analysis of the association of FTO SNP (rs9939609) with the expression of classical phenotype of PCOS: a Sri Lankan study.

Authors:  Umayal Branavan; Sulochana Wijesundera; Vishvanath Chandrasekaran; Carukshi Arambepola; Chandrika Wijeyaratne
Journal:  BMC Med Genet       Date:  2020-02-12       Impact factor: 2.103

Review 6.  Skin disease related to metabolic syndrome in women.

Authors:  Angelica Misitzis; Paulo R Cunha; George Kroumpouzos
Journal:  Int J Womens Dermatol       Date:  2019-07-04

7.  Age at Menarche and Menopause, Reproductive Lifespan, and Risk of Cardiovascular Events Among Chinese Postmenopausal Women: Results From a Large National Representative Cohort Study.

Authors:  Lu Chen; Zhen Hu; Xin Wang; Yuxin Song; Zuo Chen; Linfeng Zhang; Congyi Zheng; Jillian Vallis; Haoqi Zhou; Xue Cao; Yixin Tian; Jiayin Cai; Runqing Gu; Yilin Huang; Zengwu Wang
Journal:  Front Cardiovasc Med       Date:  2022-09-09

8.  Metabolic and Endocrine Characteristics of Indian Women with Polycystic Ovary Syndrome.

Authors:  Amar Nagesh Kumar; Jupalle Nagaiah Naidu; Uppala Satyanarayana; Krishnan Ramalingam; Medabalmi Anitha
Journal:  Int J Fertil Steril       Date:  2016-04-05

9.  Polycystic ovary syndrome (PCOS) and kisspeptin - A Sri Lankan study.

Authors:  B Umayal; S N Jayakody; N V Chandrasekharan; W Ss Wijesundera; C N Wijeyaratne
Journal:  J Postgrad Med       Date:  2019 Jan-Mar       Impact factor: 1.476

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.